Simon Rule, MD, Stephen M. Ansell, MD, PhD, and Anas Younes, MD
In this video, “New Strategies for Aggressive B-Cell Lymphomas”, Simon Rule, MD, Stephen M. Ansell, MD, PhD and Anas Younes, MD discuss current thinking and future opportunities for improving outcomes in diffuse large B-cell lymphoma (DLBCL).
Novel therapies – Ibrutinib, lenalidomide, and venetoclax – are used in relapsed/refractory (R/R) DLBCL. Several trials have evaluated new therapies in frontline regimens but, unfortunately, R-CHOP remains the standard. In R/R DLBCL, where there is still major unmet need, CAR-T cells are making a substantial impact and a variety of innovative targets and immune therapies are in development.